IPCIQ (IntelliPharmaCeutics International) 3-Year EBITDA Growth Rate: 0.00% (As of Aug. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPCIQ IntelliPharmaCeutics International Inc IPCIQ
16 GF Score
Price $0.15
View Full Analysis

What is IntelliPharmaCeutics International 3-Year EBITDA Growth Rate?

IntelliPharmaCeutics International IPCIQ -100.00% 16 3-Year EBITDA Growth Rate is 0.00% as of Aug. 2023. GuruFocus rates IPCIQ with a GF Score™ of 16/100.

IntelliPharmaCeutics International's EBITDA per Share for the three months ended in Aug. 2023 was $-0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

IntelliPharmaCeutics International  (OTCPK:IPCIQ) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

IntelliPharmaCeutics International 3-Year EBITDA Growth Rate Related Terms

IPCIQ vs CHRO, KTTA, FRTX: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate falls into.


IPCIQ
16GF Score
IntelliPharmaCeutics International Inc IPCIQ
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IntelliPharmaCeutics International 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
IntelliPharmaCeutics International (IPCIQ) has a 3-Year EBITDA Growth Rate of 0.00% as of Aug. 2023. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IntelliPharmaCeutics International and its competitors.
Is IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate too high?
IntelliPharmaCeutics International's current 3-Year EBITDA Growth Rate is 0.00%. Overall, IntelliPharmaCeutics International has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate compare to CHRO and KTTA?
IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. The industry median 3-Year EBITDA Growth Rate is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IntelliPharmaCeutics International and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IntelliPharmaCeutics International's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IntelliPharmaCeutics International stock overvalued right now?
IntelliPharmaCeutics International (IPCIQ) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. IntelliPharmaCeutics International's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For IntelliPharmaCeutics International (IPCIQ), the current 3-Year EBITDA Growth Rate is 0.00% as of Aug. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IntelliPharmaCeutics International Business Description

Address 30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline.
16GF Score

Get the complete analysis for IPCIQ

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price